Mesoblast Limited

Mesoblast Limited (ASX: MSB; NASDAQ: MESO) is developing advanced biotherapeutics based on its broad, proprietary and patented allogeneic adult Mesenchymal Precursor Cell (MPC) technology platform.

This novel technology is being developed to focus on medical conditions with unmet needs such as diabetes and its complications, inflammatory and immune diseases of the joints and lungs, vertebral spine conditions, eye diseases and cardiovascular diseases.

Mesoblast's cash reserves (~$179 million at 31 December 2012) enable simultaneous product development with future revenues expected from milestone payments, distribution arrangements and direct sales.

Publicly-listed on the Australian Securities Exchange (ASX) since 2004, there are approximately 288 million shares on issue, with approximately 80% ownership by institutional and sophisticated investors.

Business Description

• Adult stem cell technology platform
• High margin allogeneic or 'off-the-shelf' products readily available at time and place of need.
• Patented MPCs have the ability to be ex-vivo expanded, are immuno-tolerant, and do not require donor/recipient matching
• MPCs are batched produced, with each batch being highly reproducible and consistent.

Alliances

Mesoblast has formed a strategic alliance with Teva Pharmaceutical Industries to develop and commercialize potential stem cell therapeutics for cardiovascular and central nervous system indications.

An agreement with biologics manufacturer, Lonza, has been formed for clinical and long-term commercial production of Mesoblast's allogeneic adult stem cell products. The alliance provides Mesoblast with significant commercial advantages, including certainty of capacity to meet long-term global supply of its proprietary MPC products.

Intellectual Property

Mesoblast has been granted key patents by the United States Patent and Trade Mark Office and the State Intellectual Property Office of the People's Republic of China. These patents deliver major commercial advantages and offer long term protection in these territories for the company's products based on its proprietary MPC adult stem cell technology platform. In the United States, Mesoblast has patents which confer exclusive rights through to March 2029 to compositions-of-matter covering its current products. In China, two key patents provide Mesoblast with exclusive MPC product commercial rights and protection through to 2025. These patents provide Mesoblast with long-term composition-of-matter protection for the company's MPC products derived from an unlimited range of tissue sources, such as bone marrow, adipose tissue, placenta, umbilical cord, and dental pulp. These Chinese patents underpin Mesoblast's corporate strategy to target the world's largest emerging market for regenerative medicines, and to protect its manufacturing processes and know-how. Additional patents cover specific uses of the company's biologic products that considerably extend the duration of patent protection.

updated 18th November, 2015

© Copyright 1996-2019 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.